Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor

Sangbin Lee, Jiyeon Kim, Gayong Shim, Sunil Kim, Su Eun Han, Kwang Meyung Kim, Ick Chan Kwon, Yongseok Choi, Young Bong Kim, Chan Wha Kim, Yu Kyoung Oh

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Nanoparticles have demonstrated potential for promoting drug delivery to tumor sites and enhancing uptake. Here, we report tetraiodothyroacetic acid (tetrac) as a promising new targeting moiety for delivery of anticancer drugs to tumor tissues. Tetrac, an antagonist that blocks the binding of thyroid hormone to integrin αvβ3, was covalently linked to the activated end of pegylated lipid and used to formulate tetrac-tagged pegylated liposomes (TPL). After incubating with TPL for 9 h, cellular accumulation efficiency into A375 human melanoma cells, which express integrin αvβ3 at high density, was high (98.5% ± 0.5% of cells), whereas that in KB cells, which express integrin at a very low density, was much lower (35.1% ± 4.5%). Molecular imaging revealed that TPL preferentially distributed to tumor tissues after systemic administration in mice, where as non-targeting pegylated liposomes were distributed to tumors at background levels. Treatment with the alkyl lysophospholipid anticancer drug edelfosine, encapsulated in TPL, significantly reduced the survival of A375 tumor cells compared to cells treated with edelfosine in pegylated liposomes or with lysophosphatidylcholine encapsulated in TPL. Moreover, intravenous administration of edelfosine in TPL significantly reduced the growth of tumors and prolonged the survival of A375-xenografted mice, providing 100% protection for up to 50 days and some protection until 66 days (0% survival endpoint). In contrast, no untreated mice or mice treated with edelfosine-loaded pegylated liposomes survived up to 50 or 48 days, respectively, after tumor inoculation. These results suggest the potential of tetrac as a new ligand moiety for enhancing the delivery of anticancer drug-loaded nanoparticles to tumors and enhancing the therapeutic efficacy of encapsulated anticancer drugs.

Original languageEnglish
Pages (from-to)213-220
Number of pages8
JournalJournal of Controlled Release
Volume164
Issue number2
DOIs
Publication statusPublished - 2012 Dec 10

Fingerprint

Integrins
Liposomes
Pharmaceutical Preparations
Neoplasms
Nanoparticles
Survival
Lysophospholipids
KB Cells
tetraiodothyroacetic acid
Lysophosphatidylcholines
Molecular Imaging
Thyroid Hormones
Intravenous Administration
Melanoma
Ligands
Lipids
edelfosine
Therapeutics
Growth

Keywords

  • Anticancer drug
  • Edelfosine
  • Integrin receptor
  • Liposome
  • Tetraiodothyroacetic acid

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor. / Lee, Sangbin; Kim, Jiyeon; Shim, Gayong; Kim, Sunil; Han, Su Eun; Kim, Kwang Meyung; Kwon, Ick Chan; Choi, Yongseok; Kim, Young Bong; Kim, Chan Wha; Oh, Yu Kyoung.

In: Journal of Controlled Release, Vol. 164, No. 2, 10.12.2012, p. 213-220.

Research output: Contribution to journalArticle

Lee, Sangbin ; Kim, Jiyeon ; Shim, Gayong ; Kim, Sunil ; Han, Su Eun ; Kim, Kwang Meyung ; Kwon, Ick Chan ; Choi, Yongseok ; Kim, Young Bong ; Kim, Chan Wha ; Oh, Yu Kyoung. / Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor. In: Journal of Controlled Release. 2012 ; Vol. 164, No. 2. pp. 213-220.
@article{7effd6f9cf654d06b03568fbc44ff9ad,
title = "Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor",
abstract = "Nanoparticles have demonstrated potential for promoting drug delivery to tumor sites and enhancing uptake. Here, we report tetraiodothyroacetic acid (tetrac) as a promising new targeting moiety for delivery of anticancer drugs to tumor tissues. Tetrac, an antagonist that blocks the binding of thyroid hormone to integrin αvβ3, was covalently linked to the activated end of pegylated lipid and used to formulate tetrac-tagged pegylated liposomes (TPL). After incubating with TPL for 9 h, cellular accumulation efficiency into A375 human melanoma cells, which express integrin αvβ3 at high density, was high (98.5{\%} ± 0.5{\%} of cells), whereas that in KB cells, which express integrin at a very low density, was much lower (35.1{\%} ± 4.5{\%}). Molecular imaging revealed that TPL preferentially distributed to tumor tissues after systemic administration in mice, where as non-targeting pegylated liposomes were distributed to tumors at background levels. Treatment with the alkyl lysophospholipid anticancer drug edelfosine, encapsulated in TPL, significantly reduced the survival of A375 tumor cells compared to cells treated with edelfosine in pegylated liposomes or with lysophosphatidylcholine encapsulated in TPL. Moreover, intravenous administration of edelfosine in TPL significantly reduced the growth of tumors and prolonged the survival of A375-xenografted mice, providing 100{\%} protection for up to 50 days and some protection until 66 days (0{\%} survival endpoint). In contrast, no untreated mice or mice treated with edelfosine-loaded pegylated liposomes survived up to 50 or 48 days, respectively, after tumor inoculation. These results suggest the potential of tetrac as a new ligand moiety for enhancing the delivery of anticancer drug-loaded nanoparticles to tumors and enhancing the therapeutic efficacy of encapsulated anticancer drugs.",
keywords = "Anticancer drug, Edelfosine, Integrin receptor, Liposome, Tetraiodothyroacetic acid",
author = "Sangbin Lee and Jiyeon Kim and Gayong Shim and Sunil Kim and Han, {Su Eun} and Kim, {Kwang Meyung} and Kwon, {Ick Chan} and Yongseok Choi and Kim, {Young Bong} and Kim, {Chan Wha} and Oh, {Yu Kyoung}",
year = "2012",
month = "12",
day = "10",
doi = "10.1016/j.jconrel.2012.05.043",
language = "English",
volume = "164",
pages = "213--220",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor

AU - Lee, Sangbin

AU - Kim, Jiyeon

AU - Shim, Gayong

AU - Kim, Sunil

AU - Han, Su Eun

AU - Kim, Kwang Meyung

AU - Kwon, Ick Chan

AU - Choi, Yongseok

AU - Kim, Young Bong

AU - Kim, Chan Wha

AU - Oh, Yu Kyoung

PY - 2012/12/10

Y1 - 2012/12/10

N2 - Nanoparticles have demonstrated potential for promoting drug delivery to tumor sites and enhancing uptake. Here, we report tetraiodothyroacetic acid (tetrac) as a promising new targeting moiety for delivery of anticancer drugs to tumor tissues. Tetrac, an antagonist that blocks the binding of thyroid hormone to integrin αvβ3, was covalently linked to the activated end of pegylated lipid and used to formulate tetrac-tagged pegylated liposomes (TPL). After incubating with TPL for 9 h, cellular accumulation efficiency into A375 human melanoma cells, which express integrin αvβ3 at high density, was high (98.5% ± 0.5% of cells), whereas that in KB cells, which express integrin at a very low density, was much lower (35.1% ± 4.5%). Molecular imaging revealed that TPL preferentially distributed to tumor tissues after systemic administration in mice, where as non-targeting pegylated liposomes were distributed to tumors at background levels. Treatment with the alkyl lysophospholipid anticancer drug edelfosine, encapsulated in TPL, significantly reduced the survival of A375 tumor cells compared to cells treated with edelfosine in pegylated liposomes or with lysophosphatidylcholine encapsulated in TPL. Moreover, intravenous administration of edelfosine in TPL significantly reduced the growth of tumors and prolonged the survival of A375-xenografted mice, providing 100% protection for up to 50 days and some protection until 66 days (0% survival endpoint). In contrast, no untreated mice or mice treated with edelfosine-loaded pegylated liposomes survived up to 50 or 48 days, respectively, after tumor inoculation. These results suggest the potential of tetrac as a new ligand moiety for enhancing the delivery of anticancer drug-loaded nanoparticles to tumors and enhancing the therapeutic efficacy of encapsulated anticancer drugs.

AB - Nanoparticles have demonstrated potential for promoting drug delivery to tumor sites and enhancing uptake. Here, we report tetraiodothyroacetic acid (tetrac) as a promising new targeting moiety for delivery of anticancer drugs to tumor tissues. Tetrac, an antagonist that blocks the binding of thyroid hormone to integrin αvβ3, was covalently linked to the activated end of pegylated lipid and used to formulate tetrac-tagged pegylated liposomes (TPL). After incubating with TPL for 9 h, cellular accumulation efficiency into A375 human melanoma cells, which express integrin αvβ3 at high density, was high (98.5% ± 0.5% of cells), whereas that in KB cells, which express integrin at a very low density, was much lower (35.1% ± 4.5%). Molecular imaging revealed that TPL preferentially distributed to tumor tissues after systemic administration in mice, where as non-targeting pegylated liposomes were distributed to tumors at background levels. Treatment with the alkyl lysophospholipid anticancer drug edelfosine, encapsulated in TPL, significantly reduced the survival of A375 tumor cells compared to cells treated with edelfosine in pegylated liposomes or with lysophosphatidylcholine encapsulated in TPL. Moreover, intravenous administration of edelfosine in TPL significantly reduced the growth of tumors and prolonged the survival of A375-xenografted mice, providing 100% protection for up to 50 days and some protection until 66 days (0% survival endpoint). In contrast, no untreated mice or mice treated with edelfosine-loaded pegylated liposomes survived up to 50 or 48 days, respectively, after tumor inoculation. These results suggest the potential of tetrac as a new ligand moiety for enhancing the delivery of anticancer drug-loaded nanoparticles to tumors and enhancing the therapeutic efficacy of encapsulated anticancer drugs.

KW - Anticancer drug

KW - Edelfosine

KW - Integrin receptor

KW - Liposome

KW - Tetraiodothyroacetic acid

UR - http://www.scopus.com/inward/record.url?scp=84869493371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869493371&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.05.043

DO - 10.1016/j.jconrel.2012.05.043

M3 - Article

C2 - 22664473

AN - SCOPUS:84869493371

VL - 164

SP - 213

EP - 220

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -